Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pro Dex (PDEX) Total Liabilities (2016 - 2025)

Pro Dex's Total Liabilities history spans 12 years, with the latest figure at $20.6 million for Q4 2025.

  • For Q4 2025, Total Liabilities fell 27.76% year-over-year to $20.6 million; the TTM value through Dec 2025 reached $20.6 million, down 27.76%, while the annual FY2025 figure was $24.6 million, 13.65% up from the prior year.
  • Total Liabilities for Q4 2025 was $20.6 million at Pro Dex, down from $22.8 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $29.0 million in Q1 2025 and bottomed at $18.4 million in Q3 2023.
  • The 5-year median for Total Liabilities is $21.7 million (2022), against an average of $22.3 million.
  • The largest YoY upside for Total Liabilities was 67.74% in 2021 against a maximum downside of 32.62% in 2021.
  • A 5-year view of Total Liabilities shows it stood at $20.1 million in 2021, then rose by 17.55% to $23.6 million in 2022, then dropped by 16.91% to $19.6 million in 2023, then surged by 45.37% to $28.6 million in 2024, then decreased by 27.76% to $20.6 million in 2025.
  • Per Business Quant, the three most recent readings for PDEX's Total Liabilities are $20.6 million (Q4 2025), $22.8 million (Q3 2025), and $24.6 million (Q2 2025).